Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection
Daisuke Tokuhara, … , Lennart Hammarström, Yoshikazu Yuki
Daisuke Tokuhara, … , Lennart Hammarström, Yoshikazu Yuki
Published August 8, 2013
Citation Information: J Clin Invest. 2013;123(9):3829-3838. https://doi.org/10.1172/JCI70266.
View: Text | PDF
Research Article Infectious disease

Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection

  • Text
  • PDF
Abstract

Rotavirus-induced diarrhea is a life-threatening disease in immunocompromised individuals and in children in developing countries. We have developed a system for prophylaxis and therapy against rotavirus disease using transgenic rice expressing the neutralizing variable domain of a rotavirus-specific llama heavy-chain antibody fragment (MucoRice-ARP1). MucoRice-ARP1 was produced at high levels in rice seeds using an overexpression system and RNAi technology to suppress the production of major rice endogenous storage proteins. Orally administered MucoRice-ARP1 markedly decreased the viral load in immunocompetent and immunodeficient mice. The antibody retained in vitro neutralizing activity after long-term storage (>1 yr) and boiling and conferred protection in mice even after heat treatment at 94°C for 30 minutes. High-yield, water-soluble, and purification-free MucoRice-ARP1 thus forms the basis for orally administered prophylaxis and therapy against rotavirus infections.

Authors

Daisuke Tokuhara, Beatriz Álvarez, Mio Mejima, Tomoko Hiroiwa, Yuko Takahashi, Shiho Kurokawa, Masaharu Kuroda, Masaaki Oyama, Hiroko Kozuka-Hata, Tomonori Nochi, Hiroshi Sagara, Farah Aladin, Harold Marcotte, Leon G.J. Frenken, Miren Iturriza-Gómara, Hiroshi Kiyono, Lennart Hammarström, Yoshikazu Yuki

×

Figure 3

MucoRice-ARP1–mediated protection in a mouse pup model of RV infection.

Options: View larger image (or click on image) Download as PowerPoint
MucoRice-ARP1–mediated protection in a mouse pup model of RV infection.
...
(A) Prophylactic administration of MucoRice-ARP1 containing rice water (8.5 μg of ARP1) given to 4-day-old neonatal mouse litters 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. Results are shown as percentage of mice with diarrhea and mean diarrhea severity. (B) Prophylactic administration of long-term stored MucoRice-ARP1 containing rice water given 9 hours prior to RRV inoculation and subsequently given twice daily for 4 consecutive days. (C) Therapeutic administration of MucoRice-ARP1 (8.5 μg of ARP1) given 9 hours after RRV inoculation and subsequently given twice daily for 4 consecutive days. Statistical significance among groups was calculated using the Kruskal-Wallis test followed by the Mann-Whitney U test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts